Factors Influencing Fluoroquinolone Resistance-Reference-Cited by-同舟云学术

Factors Influencing Fluoroquinolone Resistance

Published:2003-12 Issue:12 Volume:9 Page:1651-1654
ISSN:1080-6040
Container-title:Emerging Infectious Diseases
language:
Short-container-title:Emerg. Infect. Dis.

Author:

Sahm Daniel F.¹,Thornsberry Clyde¹,Jones Mark E.¹,Karlowsky James A.¹

Affiliation:

1. Focus Technologies, Herndon, Virginia, USA

Publisher

Centers for Disease Control and Prevention (CDC)

Subject

Infectious Diseases,Microbiology (medical),Epidemiology

Reference31 articles.

1. Maintaining fluoroquinolone class efficacy: review of influencing factors.;Scheld;Emerg Infect Dis,2003

2. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States.;Karlowsky;Int J Antimicrob Agents,2002

3. Blosser-Middleton RS, Sahm D, Evangelista AT, Thornsberry C, Jones ME, Critchley IA, Antimicrobial susceptibilities of common pathogens causing nosocomial pneumonia: 2001–2002 TRUST surveillance. Annual Meeting Infectious Disease Society of America, 2002, abstract 71.

4. Verhoef, Fluit AC. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates.;Milatovic;Antimicrob Agents Chemother,2000

5. Does dose matter?;Craig;Clin Infect Dis,2001

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Macrolide Resistance in Cases of Community-Acquired Bacterial Pneumonia in the Emergency Department;The Journal of Emergency Medicine;2018-09

2. Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties;Infectious Diseases and Therapy;2018-03-31

3. MOLECULAR BACKGROUND OF FLUOROQUINOLONE RESISTANCE IN PATHOGENIC HUMAN MYCOPLASMAS;Russian Journal of Infection and Immunity;2017-01-01

4. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones;Clinical Microbiology and Infection;2006

5. In Vitro and In Vivo Potency of Moxifloxacin and Moxifloxacin Ophthalmic Solution 0.5%, A New Topical Fluoroquinolone;Survey of Ophthalmology;2005-11